Opko Health Stock Surges 33% on Strong Q2 Earnings and Raised Guidance
Opko Health (NASDAQ: OPK) saw its stock price surge over 33% on Tuesday following a well-received quarterly earnings report. The company reported Q2 2026 revenue of $163.5 million, a 4% year-over-year increase, beating analyst consensus of $131 million. Net loss narrowed significantly to $8.4 million ($0.01 per share) from over $148 million a year ago, also beating estimates of a $0.08 per share loss. The pharmaceuticals segment drove growth with revenue rising to $89 million, boosted by higher sales volumes and a $29.4 million licensing gain. Diagnostics revenue declined to $74.5 million, partly due to the divestiture of oncology assets in September 2025. Opko raised its full-year 2026 revenue guidance to $560-585 million, up from the prior $530-560 million range and above analyst consensus of $537 million. The article notes the company appears leaner after shedding its oncology business and may approach profitability soon.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection